Novartis Unveils Promising Phase III Data for Ianalumab in Sjögren’s Disease at ACR Convergence
As reported by drugs.com, at the American College of Rheumatology (ACR) Convergence congress, Novartis presented encouraging results from its Phase III NEPTUNUS-1 and NEPTUNUS-2 trials, highlighting the potential of ianalumab…